Showing results (151-160 of 254) with videos related to
Sort By:
Pageof 26
British Journal of Haematology|July 20, 2024
Improving disease-specific survival for patients with Sezary syndrome in the modern era of systemic therapiesBelinda A Campbell, Gabor Dobos, Zahra Haider, et al.Blood Advances|August 30, 2023
International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategiesBelinda A Campbell, Gabor Dobos, Zahra Haider, et al.Blood|February 5, 2011
Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopeniaMark J Bishton, Simon J Harrison, Benjamin P Martin, et al.Leukemia & Lymphoma|March 8, 2017
Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trialsAndrei Shustov, Bertrand Coiffier, Steven Horwitz, et al.Journal of Cancer Survivorship : Research and Practice|February 2, 2017
The course of anxiety, depression and unmet needs in survivors of diffuse large B cell lymphoma and multiple myeloma in the early survivorship periodDevesh Oberoi, Victoria White, John Seymour, et al.Leukemia & Lymphoma|October 15, 2015
Dose-reduced fludarabine, cyclophosphamide and rituximab is well tolerated in older patients with chronic lymphocytic leukemia and has preserved therapeutic efficacyThomas E Lew, Chan Y Cheah, Dennis A Carney, et al.British Journal of Haematology|August 12, 2009
Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin LymphomaMichael Dickinson, David Ritchie, Daniel J DeAngelo, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2009
Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myelomaMark A Dawson, Stephen S Opat, Yamna Taouk, et al.Blood|September 14, 2011
A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myelomaSimon J Harrison, Hang Quach, Emma Link, et al.Cancer Immunology Research|February 26, 2015
CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target CellsAlexander J Davenport, Misty R Jenkins, Ryan S Cross, et al.Pageof 26